Dordaviprone Approved for H3 K27M-mutated Diffuse Midline Glioma
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline...
Progress Against Cancer
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline...
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug...
The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration...
The FDA has approved datopotamab deruxtecan-dlnk for certain patients with non-small cell lung cancer. The U.S. Food and Drug...
The FDA has approved tafasitamab-cxix for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has...
The FDA has approved pembrolizumab for certain patients with previously untreated head and neck cancer. The U.S. Food and...
The FDA has approved mitomycin intravesical solution for certain patients with recurrent non-muscle invasive bladder cancer. The U.S. Food...
The FDA has approved taletrectinib for certain patients with ROS1-mutated lung cancer. The U.S. Food and Drug Administration (FDA)...
The FDA has approved darolutamide for metastatic castration-sensitive prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell...